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AbstrACt
Objectives The Social Appearance Anxiety Scale (SAAS) is 
a 16-item measure that assesses social anxiety in situations 
where appearance is evaluated. The objective was to use 
optimal test assembly (OTA) methods to develop and validate 
a short-form SAAS based on objective and reproducible 
criteria.
Design This study was a cross-sectional analysis of baseline 
data from adults enrolled in the Scleroderma Patient-centered 
Intervention Network (SPIN) Cohort.
setting Adults in the SPIN Cohort in the present study were 
enrolled at 28 centres in Canada, the USA and the UK.
Participants The SAAS was administered to 926 adults 
with scleroderma.
Primary and secondary measures The SAAS, Brief 
Fear of Negative Evaluation II (BFNE II), Brief Satisfaction 
with Appearance Scale (Brief-SWAP), Patient Health 
Questionnaire-8 (PHQ8) and Social Interaction Anxiety 
Scale-6 (SIAS-6) were collected, as well as demographic 
characteristics.
results OTA methods identified a maximally informative 
shortened version for each possible form length between 1 
and 15 items. The final shortened version was selected based 
on prespecified criteria for reliability, concurrent validity and 
statistically equivalent convergent validity with the BFNE II 
scale. A five-item short version was selected (SAAS-5). The 
SAAS-5 had a Cronbach’s α of 0.95 and had high concurrent 
validity with the full-length form (r=0.97). The correlation of 
the SAAS-5 with the BFNE II was 0.66, which was statistically 
equivalent to that of the full-length form. Furthermore, the 
correlation of the SAAS-5 with the two subscales of the Brief-
SWAP, and the SIAS-6, were statistically equivalent to that of 
the full-length form.
Conclusions OTA was an efficient method for shortening 
the full-length SAAS to create the SAAS-5.
IntrODuCtIOn 
Patient-reported outcome measures (PROs) 
that assess patient health, well-being and 
psychological status based on patient perspec-
tives are increasingly a central component 
of clinical trials and cohort-based observa-
tional studies in health research.1 This can 
lead, however, to participants being asked 
to respond to many scales that each contain 
multiple items, which may be a burden 
for participants, increase research costs 
and contribute to poor quality data due to 
survey fatigue. To ameliorate this problem, 
researchers sometimes attempt to create 
shortened versions of PROs with scores that 
can perform as well or nearly as well as orig-
inal full-length versions.2–5 
In rare diseases, including systemic scle-
rosis (SSc), psychological impact can be 
substantial, and psychological measures 
are increasingly included in large, multisite 
studies. SSc is a rare autoimmune disorder 
characterised by thickening and fibrosis of 
the skin and internal organs.6 7 Changes in 
appearance are a hallmark of the disease 
and can include hypopigmentation and 
hyperpigmentation, digital ulcers, hand 
strengths and limitations of this study
 ► This study used optimal test assembly methods and 
equivalence testing to shorten the Social Appearance 
Anxiety Scale (SAAS) in patients with scleroderma.
 ► This method is data  driven and reproducible, un-
like many alternative methods for shortening 
questionnaires.
 ► The generalisability of findings is limited to adults 
with scleroderma and should be confirmed for 
other patient populations as well as the general 
population.
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contractures, telangiectasias and altered facial features. 
Changes in appearance often occur in socially relevant 
areas (ie, hands and face) of the body and can have signif-
icant impacts on psychosocial functioning, in particular 
in social contexts.8 Adults with SSc report high rates of 
anxiety, with 64% reporting at least one anxiety disorder 
in their lifetime, and social anxiety being among the most 
common.9 Despite reports of appearance-related social 
discomfort, research in appearance-related social anxiety 
among adults with SSc is limited.
The Social Appearance Anxiety Scale (SAAS)10 is a 
16-item self-report measure that assesses fear of situa-
tions in which one’s appearance will be evaluated. The 
SAAS was recently validated in a large sample (n=938) 
of adults with SSc attending clinics in Canada, the USA 
and the UK.11 Consistent with previous studies,10 12–14 a 
unidimensional factor structure fits well among the total 
sample of adults with SSc. Internal consistency reliability 
as measured by Cronbach’s α was excellent in the total 
sample (α=0.96) and for limited (α=0.96) and diffuse 
(α=0.97) subtypes. Evidence of convergent validity was 
provided via moderate to large correlations between the 
16-item SAAS and measures of social discomfort, fear of 
negative evaluation, social anxiety, symptoms of depres-
sion and dissatisfaction with appearance. In other studies, 
the SAAS has also demonstrated strong measurement 
properties in samples of university students,10 12 women 
with eating disorders13 and gay and bisexual men of 
colour.14 No studies, however, have examined whether 
all 16 items of the SAAS are necessary to achieve these 
measurement properties or whether it is possible to 
shorten this scale. Apparent redundancy between some 
of the 16 items suggest that there may be an opportunity 
for shortening (eg, item 7, ‘I am afraid people find me 
unattractive’, and item 16, ‘I am concerned that people 
think I am not good looking’.).
Historically, researchers have created shortened 
versions of PROs through either an expert-based, qual-
itative assessment of item content or by fitting a factor 
analysis model and removing items with minimal factor 
loadings or low item–total correlations.3 More modern 
techniques, such as item response theory,15 have been 
used to identify items that are problematic. However, 
these methods often are administered in a way that the 
final selection of items in the shortened version is left to 
the researcher’s discretion, rather than by systematically 
establishing prespecified cut-offs or using reproducible 
criteria.
Optimal test assembly (OTA) is a branch-and-bound, 
mixed integer programming procedure that relies on 
estimates obtained from an item response theory model 
to select an optimal subset of items that best satisfy objec-
tive, reproducible and prespecified constraints.16 OTA 
has been commonly used to create versions of high-stakes 
educational tests,17 but recently, a study demonstrated 
its use for the development of shortened versions of 
PROs in health research by shortening an 18-item hand 
function scale to six items while maintaining equivalent 
measurement properties to those of the full-length 
form.18 Furthermore, OTA was recently used to shorten 
the Patient Health Questionnaire – 9 to a four-item 
shortened form.19 This procedure was also shown to be 
replicable, reproducible and produce shortened forms 
of minimal length as compared with leading alternative 
methods.20
The objective of the present study was to apply OTA to 
develop a shortened version of the SAAS. We: (1) used 
OTA methods to generate maximally precise candidate 
short versions of the SAAS of each possible length; (2) 
selected the shortest possible version that performed 
similarly to the full-form SAAS in terms of prespeci-
fied reliability and validity criteria; and (3) assessed the 
convergent validity of the final selected shortened form 
as compared with that of the full-length form.
MAterIAl AnD MethODs
Participants and procedures
This study was a cross-sectional analysis of baseline data 
from adults enrolled in the Scleroderma Patient-centered 
Intervention Network (SPIN) Cohort21 who completed 
online study questionnaires from May 2014 to August 
2016. Adults in the SPIN Cohort in the present study were 
enrolled at 28 centres in Canada, the USA and the UK. 
To be eligible for the SPIN Cohort, adults must be classi-
fied as having SSc according to 2013 American College of 
Rheumatology (ACR)/European League Against Rheu-
matism (EULAR) classification criteria22 and confirmed 
by a SPIN physician, be at least 18 years of age, have the 
ability to provide informed consent and be fluent in 
English, French or Spanish. Eligible adults are invited 
by the attending physician or a supervised nurse coordi-
nator to participate in the cohort, and written informed 
consent is obtained. SPIN Cohort adults complete 
outcome measures via the internet on enrolment and 
subsequently every 3 months. Adults who completed all 
items of the SAAS and the Brief Fear of Negative Evalua-
tion II (BFNE II) at baseline in English were included in 
the present study.
Measures
Demographic and medical variables
Age, gender, marital status, number of years since first 
non-Raynaud’s symptom, disease subtype (limited or 
diffuse)and modified Rodnan skin score23 were collected. 
Limited disease was defined as skin sclerosis confined to 
the limbs distal to the elbows and knees with or without 
face involvement. Diffuse disease was defined as skin scle-
rosis involving the limbs proximal to the elbows and knees 
with or without chest or trunk involvement.24 Demo-
graphic variables were self-reported, and SPIN physicians 
or nurse coordinators collected medical variables.
Social Appearance Anxiety Scale
The SAAS, a 16-item measure, was developed to assess 
the respondent’s anxiety surrounding situations in which 
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one’s appearance may be evaluated. Response options 
for each item range from 1 (not at all) to 5 (extremely). 
The total score is calculated by summing across all items, 
after reverse coding the first item. Scores range from 16 
to 80, with higher scores indicating greater fear. A study 
of adults with SSc found strong evidence for a one-di-
mension factor structure both in the total sample and 
when examined separately among adults with limited and 
diffuse SSc, internal consistency reliability and conver-
gent validity.11
Brief Fear of Negative Evaluation II
The BFNE-II is a 12-item measure that assesses the degree 
to which individuals worry about how they are perceived 
and evaluated by others.25 Response options for each 
item range from 1 (not at all characteristic of me) to 5 
(extremely characteristic of me). Scores range from 12 
to 60 with higher scores indicating greater fear of nega-
tive evaluation. A study of adults with SSc found strong 
evidence for a one-dimension factor structure, internal 
consistency reliability and convergent validity.26
Brief Satisfaction with Appearance Scale (Brief-SWAP)
The Brief-SWAP consists of two three-item subscales 
that measure dissatisfaction with appearance and social 
discomfort.27 Response options for each item range from 
0 (strongly disagree) to 6 (strongly agree). Scores on each 
subscale range from 0 to 18, with higher scores indicating 
greater body image dissatisfaction. A study of adults with 
SSc found high internal consistency and strong conver-
gent validity with the SAAS.11
Patient Health Questionnaire-8 (PHQ-8)
The PHQ-8 consists of eight items that measure depressive 
symptomology.28 Response options on each item range 
from 0 (not at all) to 3 (nearly every day), with a total 
score that ranges from 0 to 24. Higher scores indicate 
higher levels of depressive symptoms. A study of adults 
with SSc found high internal consistency and moderate 
convergent validity with the SAAS.11
Social Interaction Anxiety Scale-6 (SIAS-6)
The SIAS-6 assesses anxiety resulting from social.29 
Response options on six items range from 0 (not at all 
characteristic or true of me) to 4 (extremely character-
istic or true of me), with total scores ranging from 0 to 24. 
A study of adults with SSc found excellent internal consis-
tency and strong convergent validity with the SAAS.11
statistical analysis
Item response theory model and OTA
Unidimensionality of the SAAS in this sample was 
confirmed previously using the same dataset as in the 
present study.11 Thus, a generalised partial credit item 
response theory model (GPCM) was fit to all 16 items of 
the SAAS.30 The GPCM estimates two types of parame-
ters for each item: threshold parameters, which measure 
the level of anxiety at which people are more likely to 
endorse a higher category than the one below it, and 
discrimination parameters, which measure the strength 
of the association between that item and the underlying 
construct (in this case, social appearance anxiety). From 
these item-level parameters, item information functions 
are estimated for each of the 16 items, and summed 
pointwise to obtain the test information function (TIF). 
The TIF measures the total amount of Fisher’s informa-
tion in the 16 items and is inversely related to the SE of 
measurement of the underlying construct. Thus, versions 
of a PRO with higher levels of test information result in 
greater precision in the measurements of the underlying 
construct.15
A set of 15 candidate shortened versions, one of each 
possible length between 1 item and 15 items, was gener-
ated through the OTA procedure. OTA uses a branch-
and-bound approach through mixed integer linear 
programming to systematically explore the space of all 
possible shortened versions of a fixed length to optimise 
an objective function. In this case, the objective function 
was defined to be the height of the TIF, thus minimising 
the SE of measurement of the underlying construct. 
Therefore, for each possible length, the OTA procedure 
creates an optimal candidate shortened version of the 
PRO, defined by selecting the items that maximise the TIF 
across the latent spectrum of the underlying construct, as 
compared with all other possible shortened versions of 
the same length. Based on previously established guide-
lines, the OTA procedure was anchored at five points 
across the spectrum of the underlying construct (−3, –1, 
0, 1, 3), jointly maximising the objective function at these 
points.16
Each of the 15 candidate short versions and the full-
length form were scored using two procedures to obtain 
estimates of each participant’s level of anxiety surrounding 
situations in which one’s appearance will be evaluated. 
First, the summed scores across all items included in the 
form were calculated by adding item scores for each item 
included in the form. Second, factor scores, which esti-
mate a level of a latent construct, were estimated from 
the GPCM for each participant for each form through an 
application of Bayes’ theorem. Although summed scores 
are typically relied on for clinical use, the factor scores 
were considered to provide a better estimate of the under-
lying construct. This is because of limitations of summed 
scores under the GPCM. Summed scores may result in an 
incorrect ordering of patients along the spectrum of the 
underlying construct. That is, patients with lower levels of 
fear may have higher summed scores than patients with 
higher levels of fear.31 32
Selection of the final form
OTA generates optimal candidate short versions of the 
SAAS but does not provide criteria by which the final 
form should be selected. When items are eliminated 
from the full-length form, the amount of test information 
inherently decreases, and there is no obvious threshold 
at which a shortened version would be said to contain 
adequate information. Therefore, the selection of the 
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final form was based on five criteria: reliability, concur-
rent validity based on summed scores, concurrent validity 
based on factor scores, convergent validity based on 
summed scores and convergent validity based on factor 
scores. Applying these five criteria concurrently ensured 
that the final selected shortened version maintains desir-
able measurement properties across these categories.
First, the reliability of each candidate shortened version 
and the full-length form was assessed using Cronbach’s 
α coefficient. The shortened version was required to 
maintain at least 95% of the value of Cronbach’s α for 
the full-length form. Second, concurrent validity for both 
summed and factor scores were assessed by calculating 
Pearson’s correlation coefficient between the scores on 
each candidate shortened version and the scores on the 
full-length form. For both the summed and factor scores, 
these correlations were required to be at least 0.95, 
ensuring that the shortened version demonstrated high 
concurrent validity.
Lastly, convergent validity was assessed through the 
correlation between each patient’s score on the SAAS 
and their score on the BFNE II. The candidate shortened 
versions were required to demonstrate statistical equiv-
alence within a tolerance of 0.05 with the convergent 
validity of the full-length SAAS through an application of 
equivalence testing. Equivalence testing, more commonly 
used in clinical trials, tests whether the difference between 
two correlations is within a prespecified range, in this 
case set at 0.05.33 34 Contrary to traditional hypothesis 
testing, equivalence testing tests a null hypothesis that the 
difference between the two correlations is greater than 
the prespecified range, against an alternative hypothesis 
of equivalence within the prespecified range. To assess 
statistical significance, we applied the Benjamini-Hoch-
berg correction procedure for each of the 30 hypothesis 
tests used (15 candidate shortened versions × two scoring 
procedures).35
Post hoc convergent validity of the shortened form
Convergent validity of the selected shortened form was 
compared with that of the full-length form. Correla-
tions between the summed scores of the selected short-
ened form and those of four other measures: the two 
subscales of the Brief-SWAP, the PHQ-8 and the SIAS-6 
were calculated. Statistical equivalence was assessed 
within a tolerance of 0.05 with the convergent validity 
of the full-length SAAS using Benjamini-Hochberg 
adjusted p values.
All analyses were conducted in R Studio V.1.0.136.36 
The GPCM was fit using the ltm package.37 The OTA anal-
ysis was conducted using the lpSolveApi package.38
Patient involvement
SPIN was conceived by a collaboration of investigators 
and patients. SPIN’s Patient Advisory Board advises the 
SPIN Steering Committee on priorities for investiga-
tion. Patients were included in the SPIN Publication 
Committee, which reviewed the proposal for the present 
study and its methods. Two patients were coauthors of the 
present report.
results
There were 926 people who completed both the SAAS 
and BFNE II. The mean age was 55.6 years, 88% were 
women and 43% had diffuse SSc. The mean±SD score on 
the SAAS was 28.3±24. SAAS scores in adults with diffuse 
SSc were significantly higher than adults with limited SSc 
(p<0.001). See table 1 for descriptive statistics.
Item response theory model and OtA
The GPCM was fit to the 16 items of the SAAS. Table 2 
shows the item content, along with the discrimination 
parameters estimated from the GPCM. The three items 
with the highest amount of discriminative ability and, 
Table 1 Patient demographic and disease characteristics 
(n=926)
Sociodemographic and 
medical variables Values
Age*, years, mean±SD (range) 55.6±11.8 (18.6–84.9)
Women, n (%) 813 (88)
Married/cohabitating, n (%) 681 (74)
Time since the onset of the 
first non-Raynaud’s symptoms, 
years†, mean±SD (range)
11.8±8.9 (0.1–46.2)
Patients with diffuse SSc, n 
(%)
399 (43)
MRSS‡, mean±SD (range) 8.0±8.8 (0–48)
SAAS score, mean 
(median)±SD (range)
28.3 (24)±13.2 (16–80)
  Mean score (median)±SD 
(range) in diffuse SSc subset
30.7 (26)±15.5 (16–80)
  Mean score (median)±SD 
(range) in limited SSc subset
16.5 (22)±11.9 (16–79)
BFNE II, mean (median)±SD 
(range)
24.7 (21)±12.1 (12–60)
Brief-SWAP Dissatisfaction 
with Appearance*, mean 
(median)±SD (range)
9.25 (9)±5.24 (0–18)
Brief-SWAP Social 
Discomfort§, mean 
(median)±SD (range)
5.33 (4)±5.26 (0–18)
PHQ-8§, mean (median)±SD 
(range)
6.14 (5)±5.35 (0–24)
SIAS-6¶, mean (median)±SD 
(range)
2.43 (1)±3.81 (0–24)
Due to missing values: *N=922; †N=861; ‡N=722; §N=921; 
¶N=920.
BFNE II, Brief Fear of Negative Evaluation II; Brief-SWAP, 
Brief Satisfaction with Appearance Scale; MRSS, modified Rodnan 
skin score; SAAS, Social Anxiety Appearance Scale; SIAS-6, 
Social Interaction Anxiety Scale-6; SSc, systemic sclerosis.
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therefore, the most influential on the TIF, were items 6, 
7 and 13. The items with the least amount of discrimina-
tive ability and, therefore, the least influential on the TIF, 
were items 1, 2 and 15. Figure 1 shows the individual item 
information functions generated from the estimates from 
the GPCM and the TIF.
The OTA procedure generated 15 candidate short 
versions that each maximised the total amount of 
test information among all shortened versions of that 
length. Online supplementary appendix table 1 shows 
the items that were selected by the OTA procedure for 
each of the 15 candidate short versions. Items 6, 7, and 
14 were included in all short forms of length at least 
three items. Although question 13 had a higher discrim-
ination parameter estimate than question 14, it was not 
included in shortened forms of lengths shorter than 4. 
This is because the OTA procedure accounts for a more 
complete assessment of an item than just its discrimi-
nation parameter.20 That is, if two items have the same 
level of discrimination, but provide information at the 
same point on the latent spectrum, then the OTA proce-
dure may not select both items into the shortened form. 
Items 1, 12, and 15 were the first three items dropped 
from the candidate shortened versions. These items 
all had low information across the spectrum of social 
appearance anxiety.
selection of the final shortened version
Table 3 presents Cronbach’s α values and concurrent 
validity correlations for the 16 candidate short forms. 
Even for shortened versions with very few items, the values 
of Cronbach’s α and the validity correlations remained 
high. Table 4 presents results of the equivalency tests for 
the convergent validity correlation with the BFNE II. The 
two-item shortened version, and all versions with at least 
four items, demonstrated statistically significant equiv-
alency for both the correlations between the summed 
and factor scores of the full SAAS with the BFNE II. All 
shortened versions with at least five items satisfied our 
prespecified criteria in terms of reliability, concurrent 
validity and convergent validity. Therefore, the five-item 
shortened version (SAAS-5, see online supplementary 
appendix table 2) was the shortest candidate version to 
fulfil our requirements. Versions shorter than the SAAS-5 
failed to meet the criteria on concurrent validity for the 
factor scores from the GPCM.
The SAAS-5 includes item 6 (‘I am concerned that 
people will find me unappealing because of my appear-
ance’), item 7 (‘I am afraid people find me unattractive’), 
item 12 (‘I am frequently afraid that I won’t meet others’ 
standards of how I should look’), item 13 (‘I worry people 
will judge the way I look negatively’) and item 14 (‘I am 
uncomfortable when I think others are noticing flaws 
in my appearance’). The SAAS-5 had a Cronbach’s α 
of 0.95 as compared with the Cronbach’s α of the full-
length form of 0.96. Thus, the SAAS-5 maintained high 
reliability. The correlation of the summed scores from 
the SAAS-5 with those from the full 16-item SAAS scores 
was r=0.97 (95% CI 0.97 to 0.97). The correlation of 
the factor scores between the full-length and shortened 
versions was r=0.95 (95% CI 0.95 to 0.96). The summed 
scores on the SAAS-5 maintained moderate-to-high posi-
tive correlation with the BFNE II (r=0.66, 95% CI 0.62 to 
0.69) compared with 0.66 (95% CI 0.63 to 0.70) for the 
16-item SAAS. Similarly, the factor scores on the SAAS-5 
maintained moderate-to-high positive correlations with 
the BFNE II (r=0.68, 95% CI 0.64 to 0.71) compared with 
0.68 (95% CI 0.64 to 0.71) for the full SAAS. The mean 
Table 2 SAAS items and discrimination parameters from 
the GPCM
Item Description
Discrimination 
parameter
1 I feel comfortable with the way I 
appear to others.
0.58
2 I feel nervous when having my 
picture taken.
0.90
3 I get tense when it is obvious people 
are looking at me.
1.57
4 I am concerned people won’t like 
me because of the way I look.
2.12
5 I worry that others talk about flaws 
in my appearance when I am not 
around.
2.30
6 I am concerned that people will 
find me unappealing because of my 
appearance.
3.28
7 I am afraid people find me 
unattractive.
3.34
8 I worry that my appearance will 
make life more difficult for me.
2.03
9 I am concerned that I have missed 
out on opportunities because of my 
appearance.
1.58
10 I get nervous when talking to people 
because of the way I look.
3.14
11 I feel anxious when other people say 
something about my appearance.
2.31
12 I am frequently afraid that I won’t 
meet others’ standards of how I 
should look.
2.94
13 I worry people will judge the way I 
look negatively.
3.24
14 I am uncomfortable when I think 
others are noticing flaws in my 
appearance.
3.00
15 I worry that a romantic partner will/
would leave me because of my 
appearance.
1.04
16 I am concerned that people think I 
am not good looking.
2.59
The SAAS is available in the public domain.
SAAS, Social Appearance Anxiety Scale.
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score on the SAAS-5 in this sample was 8.29 with an SD of 
4.55 and possible range of 5 to 25.
Post hoc convergent validity of the sAAs-5
The convergent validity of the SAAS-5 was statistically 
equivalent, within a tolerance of 0.05, to that of the full-
length SAAS for the two subscales of the Brief-SWAP, 
and the SIAS-6, as shown in table 5. The convergent 
validity correlation was not statistically equivalent for 
the PHQ-8. However, even for this measure, convergent 
validity was moderate for both the SAAS-5 and full-
length version.
DIsCussIOn
This study investigated how OTA methods can be used 
to develop shortened versions of PRO measures, using 
a measure of social appearance anxiety—the SAAS. 
Figure 1 Item and test information curves of the SAAS. The left hand plot shows the 16 individual item information curves. 
The right hand plot compares the test information functions of the full SAAS (solid line) and SAAS-5 (dashed line). SAAS, Social 
Appearance Anxiety Scale. 
Table 3 Properties of optimal shortened versions
Short form length Cronbach’s α
Correlation of summed scores with 
full form score (95% CI)
Correlation of factor scores with full 
form score (95% CI)
1 NA 0.892 (0.878 to 0.904) NA
2 0.859 0.947 (0.940 to 0.953) 0.928 (0.918 to 0.936)
3 0.921 0.957 (0.951 to 0.962) 0.928 (0.918 to 0.936)
4 0.937 0.967 (0.963 to 0.971) 0.946 (0.939 to 0.952)
5 0.947 0.969 (0.965 to 0.973) 0.952 (0.945 to 0.957)
6 0.953 0.975 (0.972 to 0.978) 0.958 (0.953 to 0.963)
7 0.959 0.978 (0.975 to 0.981) 0.964 (0.959 to 0.968)
8 0.962 0.981 (0.979 to 0.984) 0.972 (0.968 to 0.975)
9 0.965 0.983 (0.980 to 0.985) 0.975 (0.971 to 0.978)
10 0.967 0.984 (0.982 to 0.986) 0.977 (0.973 to 0.979)
11 0.969 0.987 (0.985 to 0.988) 0.980 (0.978 to 0.983)
12 0.969 0.990 (0.989 to 0.991) 0.988 (0.986 to 0.989)
13 0.970 0.992 (0.991 to 0.993) 0.989 (0.988 to 0.992)
14 0.967 0.996 (0.995 to 0.996) 0.995 (0.994 to 0.995)
15 0.967 0.997 (0.997 to 0.998) 0.996 (0.995 to 0.996)
16 0.964 1.000 (1.000 to 1.000) 1.000 (1.000 to 1.000)
Bold values represent those of the final selected short form.
NA, not applicable.
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The 16-item SAAS was shortened to a five-item version 
through a reproducible process based on prespecified 
and objective criteria. The SAAS-5 maintained high reli-
ability (α=0.95), high concurrent validity with the full-
length form, with an r=0.97 (95% CI 0.97 to 0.97) for 
summed scores, and an r=0.95 (95% CI 0.95 to 0.96) for 
factor scores. The SAAS-5 maintained statistically equiva-
lent convergent validity correlations with the BFNE II for 
both summed and factor scores. Furthermore, the SAAS-5 
maintained statistically equivalent convergent validity 
correlations for the two subscales of the Brief-SWAP 
and SIAS-6 to that of the full-length form. Although the 
SAAS-5 did not maintain a statistically equivalent conver-
gent validity correlation with the PHQ-8, this does not 
suggest poor convergent validity. This may have occurred 
because items that captured symptoms most relevant to 
depression in the SAAS are no longer included in the 
SAAS-5. Scores on the short-form remained moderately 
correlated in the expected direction with the PHQ-8.
In addition to its measurement properties, face validity, 
or the degree to which a test appears to measure what it 
reports to measure,39 is strong for the SAAS-5. The items 
of the SAAS-5 assess concern about being unappealing 
and unattractive, not meeting others’ appearance stan-
dards, worry about appearance-related judgement and 
discomfort when others notice appearance-related flaws. 
These items all appear to measure aspects of social appear-
ance anxiety, or a fear of situations in which one’s appear-
ance will be evaluated. Thus, findings from the present 
study suggest that the SAAS-5 is a brief, valid and reliable 
measure of social appearance anxiety among adults with 
SSc. The SAAS-5 may be preferred over the 16-item SAAS 
as it reduces participant burden, which is particularly 
important among adults with SSc who may have difficulty 
Table 4 Equivalency analysis results
Short form 
length
Correlations with the BFNE II (95% CI) Equivalency analysis corrected p values
Summed scores Factor scores Summed scores Factor scores
1 0.568 (0.523 to 0.611) NA 1.000 NA
2 0.644 (0.605 to 0.680) 0.653 (0.615 to 0.689) <0.001 0.003
3 0.635 (0.595 to 0.672) 0.632 (0.591 to 0.669) <0.001 0.392
4 0.651 (0.612 to 0.687) 0.657 (0.591 to 0.669) <0.001 <0.001
5 0.656 (0.618 to 0.691) 0.675 (0.638 to 0.709) <0.001 <0.001
6 0.659 (0.621 to 0.694) 0.677 (0.640 to 0.710) <0.001 <0.001
7 0.660 (0.622 to 0.695) 0.680 (0.644 to 0.713) <0.001 <0.001
8 0.661 (0.623 to 0.696) 0.680 (0.643 to 0.713) <0.001 <0.001
9 0.663 (0.625 to 0.697) 0.682 (0.646 to 0.715) <0.001 <0.001
10 0.664 (0.627 to 0.699) 0.684 (0.648 to 0.717) <0.001 <0.001
11 0.663 (0.626 to 0.699) 0.682 (0.646 to 0.717) <0.001 <0.001
12 0.670 (0.633 to 0.704) 0.688 (0.653 to 0.721) <0.001 <0.001
13 0.664 (0.626 to 0.698) 0.685 (0.649 to 0.714) <0.001 <0.001
14 0.663 (0.626 to 0.698) 0.680 (0.644 to 0.714) <0.001 <0.001
15 0.658 (0.620 to 0.693) 0.678 (0.641 to 0.711) <0.001 <0.001
16 0.664 (0.626 to 0.698) 0.679 (0.642 to 0.712) NA NA
Bold values represent those of the final selected short form.
BFNE II, Brief Fear of Negative Evaluation II; NA, not applicable.
Table 5 Convergent validity correlations
Measure Full SAAS, r (95% CI) SAAS-5, r (95% CI) 
Equivalency 
corrected p values
Brief-SWAP Dissatisfaction with Appearance 0.411 (0.356 to 0.463) 0.375 (0.318 to 0.429) 0.048
Brief-SWAP Social Discomfort 0.729 (0.697 to 0.758) 0.694 (0.659 to 0.726) 0.007
PHQ-8 0.528 (0.480 to 0.573) 0.472 (0.421 to 0.521) 0.797
SIAS-6 0.547 (0.500 to 0.591) 0.518 (0.469 to 0.563) 0.005
Brief-SWAP, Brief Satisfaction with Appearance Scale; PHQ-8, Patient Health Questionnaire-8; SAAS, Social Appearance Anxiety Scale; 
SIAS-6, Social Interaction Anxiety Scale-6.
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completing self-report questionnaires due to restricted 
physical functioning. By reducing the number of items 
in measures like the SAAS, researchers may be able to 
increase the number of constructs that are measured in 
hard-to-access populations, such as people living with rare 
diseases, including SSc.
There are several limitations that must be considered in 
this study. First, the SPIN Cohort is a convenience sample 
of patients receiving treatment at SPIN recruiting centres 
and who completed study questionnaires online. In addi-
tion, this sample had a relatively low skin score, which 
may limit the generalisability of study findings to patients 
with low disease severity.
This study used cross-sectional data, and therefore, the 
sensitivity to change or intervention status, discriminant 
validity and test–retest reliability of the SAAS-5 were not 
investigated. The purpose in the present study was to illus-
trate the use of OTA in creating a shortened version of a 
full-length form and to propose a new shortened version 
of the SAAS. Future studies should investigate these prop-
erties in order to assess the discriminant, predictive and 
evaluative characteristics of the SAAS-5. Furthermore, 
the assessment of longitudinal changes that are clinically 
meaningful due to, for example, treatment in a clinical 
trial of SSc patients, would need further study. Therefore, 
this may limit the utility of the SAAS-5 as an evaluative 
measure in patients with SSc.
The method used in this study does not include content 
validity or expert assessment of the items selected into the 
shortened form. Had an expert panel or focus group of 
patients been convened, they may have selected a different 
subset of items into the shortened form. An expert panel 
may have been able to use their knowledge to select items 
that were appropriate for the detection of clinically mean-
ingful changes of worsening or improvement. However, 
such a procedure would not rely directly on patient 
data, may not be replicable and may result in reduced 
measure validity based on imperfect clinical intuition.20 
More resource-intensive methods for developing short 
forms, such focus groups and content experts, along with 
replicable statistical criteria, would be ideal. However, the 
resources necessary to complete these procedures may 
represent a substantial barrier to the development of 
shortened forms. The OTA method provides a replicable 
method that maintains performance standards based on 
objective criteria and provides a more feasible method.
The OTA procedure is sensitive to the investigator-de-
fined choice of decision criteria in the selection of the 
final shortened version. These decision criteria, when 
applied in future studies, must be carefully considered by 
researchers. Furthermore, the OTA method treats the 16 
items of the SAAS as if they represented a full item bank 
of possible items. It is possible that if other items were 
considered that a different set of items would have been 
selected into the final shortened version.
The OTA procedure is data driven, and results of this 
study should be replicated in this patient population. An 
analysis based on one sample of SSc patients may not be 
sufficient for the derivation of a disease-specific measure. 
The results of this study are only as applicable for patients 
with SSc as the original full-length SAAS. It should be 
noted that the original SAAS was developed based on 
three different samples of volunteers from introductory 
psychology courses at large public universities. Therefore, 
even the original SAAS instrument might not provide 
sufficient coverage in terms of content validity for patients 
with SSc. Lastly, future work should assess whether the 
SAAS-5 is the optimal shortened form in other patient 
populations, as well as the general population, as results 
of this study are limited in their generalisability beyond 
patients with SSc.
COnClusIOn
In summation, this study showed how OTA methods 
might be used to shorten PROs. This method was used 
to shorten the 16-item SAAS to a five-item version while 
maintaining comparable reliability and validity among a 
sample of adults with SSc. This analysis should be repli-
cated in this patient population, as well as other patient 
populations, to increase the generalisability of these find-
ings. Moreover, expert opinions or focus groups should 
be solicited to assess whether the items selected into the 
shortened form match clinical intuition.
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